Rather, it challenges teams to make short-run and long-run resource allocation decisions in the face of a binding fiscal constraint.

FORBES: The NFL's Free Agency Frenzy: A By-Product of Football's Economics, A Contributor to NFL's Unparalleled Demand

Even if Celebrex and Bextra don't make it through the meeting, Pfizer could look like a winner to investors as long as it doesn't face a massive liability cloud like the ever-ballooning diet-drug litigation that has weighed on smaller rival Wyeth (nyse: WYE - news - people ) for years.

FORBES: Judgment Day For The FDA, Pfizer